Dupilumab treatment improves signs, symptoms, and quality of life in children aged 6 months to 11 years with moderate-to-severe atopic dermatitis: a plain language summary

Plain Language SummaryWhat is this summary about?This plain language summary presents results of 2 clinical studies in patients with atopic dermatitis (AD) or eczema:LIBERTY AD PRESCHOOL (children aged 6 months to 5 years with moderate-to-severe AD)LIBERTY AD PEDS (children aged 6 to 11 years with severe AD) It describes the effect of dupilumab treatment on skin appearance, symptoms, and quality of life in children aged 6 months to 11 years with AD ranging from moderate to severe. The studies included children who did not achieve clear or almost clear skin after 16 weeks of treatment.What were the results?These 2 studies showed that dupilumab treatment for AD led to clinically meaningful improvements (improvements that are considered important to patients) in skin appearance, symptoms, and quality of life in children aged 6 months to 11 years, including children who did not achieve clear or almost clear skin after 16 weeks of treatment.How to say (download PDF and double click sound icon to play sound)…Atopic: ay-TOP-ickDermatitis: dur-muh-TIE-tisDupilumab: doo-PILL-uw-mabAtopic dermatitis (AD): Is a long-term, inflammatory disease that impacts the whole body. Patients experience skin lesions, intense itching, disturbed sleep, and lower quality of life. Treatment options are limited for children with moderate-to-severe AD.Dupilumab: Is prescribed in multiple countries to treat AD in patients 6 months of age and older.This is an abstract of the Plain Language Summary of Publication article.